SCHEDULE: Key Investors Boost OmniAb Stake to 8.5%

Robert Goldstein and affiliated entities report an aggregate beneficial ownership of 8.5% in OmniAb, Inc. common stock as of December 31, 2025.

Summary

• Ash X LP and RLG GP LLC each beneficially own 7,557,202 shares, representing approximately 5.3% of OmniAb, Inc.'s common stock.
• RLG Capco II LLC beneficially owns 4,733,575 shares, representing approximately 3.3% of the common stock.
• Robert Goldstein, through various affiliations and direct holdings, beneficially owns an aggregate of 12,291,972 shares, representing approximately 8.5% of the common stock.
• Joel Greenblatt, through affiliations and direct holdings, beneficially owns an aggregate of 1,429,766 shares, representing approximately 1.0% of the common stock.
• The percentages are based on 143,955,400 shares of common stock outstanding as of October 28, 2025, as disclosed in OmniAb, Inc.'s Form 10-Q filed on November 4, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as increased significant ownership by established investors like Robert Goldstein and Joel Greenblatt can signal confidence in OmniAb's value proposition and future potential.

Positives

• Significant beneficial ownership by prominent investors like Robert Goldstein and Joel Greenblatt, potentially signaling confidence in OmniAb, Inc.'s long-term prospects.
• Robert Goldstein's aggregate beneficial ownership of 8.5% indicates a substantial and committed interest in the company.

Negatives

• No specific negatives are directly reported in this beneficial ownership filing.

Risks

• Concentrated ownership by a few entities and individuals could potentially influence corporate decisions or create liquidity issues if large blocks of shares are traded.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant institutional ownership, particularly from well-regarded investment managers, can often be interpreted as a vote of confidence in a company's long-term prospects within its sector. For a biotechnology company like OmniAb, Inc., such backing can be crucial for stability and future growth initiatives.

Comparison to Industry Standards

• Institutional ownership levels vary widely across industries and company sizes. For a biotech company, an 8.5% stake by a single influential investor group is notable and suggests a strong conviction, potentially above average for smaller-cap biotech firms that might have more dispersed ownership.
• Comparable companies in the early-to-mid stage biotech space often see institutional ownership ranging from 30-70%, with individual large stakes like this contributing significantly to that total.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide a degree of stability and potentially attract further institutional interest, but also means a larger block of shares is controlled by a single group.

Key Dates

Recommendation

The filing indicates a significant and stable beneficial ownership by a group of established investors, which can be a positive signal. However, a Schedule 13G filing alone does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial stake, suggesting existing holders might 'hold' based on this vote of confidence, while new investors would need further due diligence.

Keywords

OmniAb Inc., OABI, Beneficial Ownership, Schedule 13G, Institutional Investor, Robert Goldstein, Joel Greenblatt, Ash X LP, RLG GP LLC, RLG Capco II LLC, Gotham Asset Management, Common Stock